{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:05:54Z","timestamp":1791245154321,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":272,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1136\/esmoopen-2019-000659","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T04:14:27Z","timestamp":1582172067000},"page":"e000659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials"],"prefix":"10.1016","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct03747120","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02273973","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9879-6048","authenticated-orcid":false,"given":"Daniel","family":"Eiger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alice","family":"Franzoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Pond\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"de Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Schmitt Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"de Hemptinne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4509","authenticated-orcid":false,"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2019-000659_bb0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab--mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000659_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000073","article-title":"Twenty years of anti-HER2 therapy-associated cardiotoxicity","volume":"1","author":"Pond\u00e9","year":"2016","journal-title":"ESMO Open"},{"key":"10.1136\/esmoopen-2019-000659_bb0020","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","article-title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","volume":"393","author":"Earl","year":"2019","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2019-000659_bb0025","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/S0140-6736(19)30653-1","article-title":"6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial","volume":"393","author":"Pivot","year":"2019","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2019-000659_bb0030","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/annonc\/mdv213","article-title":"Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic oncology Research Group (HORG)","volume":"26","author":"Mavroudis","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000659_bb0035","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdy414","article-title":"Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study\u2021","volume":"29","author":"Conte","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000659_bb0040","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/jamaoncol.2018.1380","article-title":"Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the sold randomized clinical trial","volume":"4","author":"Joensuu","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1136\/esmoopen-2019-000659_bb0045","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/bjc.2015.405","article-title":"Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)","volume":"113","author":"Schneider","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1136\/esmoopen-2019-000659_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-018-0098-y","article-title":"PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?","volume":"5","author":"Pond\u00e9","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"10.1136\/esmoopen-2019-000659_bb0055","doi-asserted-by":"crossref","first-page":"pkz033","DOI":"10.1093\/jncics\/pkz033","article-title":"Deescalating adjuvant trastuzumab in HER2-positive early-stage breast cancer: a systemic review and meta-analysis","volume":"3","author":"Goldvaser","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"10.1136\/esmoopen-2019-000659_bb0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.522","article-title":"Do all patients with HER2-positive breast cancer require one year of adjuvant trastuzumab?: a systematic review and meta-analysis","volume":"37","author":"Stewart","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000659_bb0065","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e12057","article-title":"Short versus long duration of adjuvant trastuzumab (T) in HER2+ breast cancer: a systematic review and meta-analysis of randomized controlled trials (RCTs)","volume":"37","author":"Sipra","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000659_bb0070","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/bjc.2016.357","article-title":"Trastuzumab-associated cardiac events in the Persephone trial","volume":"115","author":"Earl","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1136\/esmoopen-2019-000659_bb0075","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ejca.2015.05.028","article-title":"Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study","volume":"51","author":"Pivot","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2019-000659_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1136\/esmoopen-2019-000659_bb0085","series-title":"Chapter 8: Assessing risk of bias in a randomized trial","author":"Higgins","year":"2019"},{"key":"10.1136\/esmoopen-2019-000659_bb0090","series-title":"Chapter 10: Analysing data and undertaking meta-analyses","author":"Deeks","year":"2019"},{"key":"10.1136\/esmoopen-2019-000659_bb0095","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1136\/esmoopen-2019-000659_bb0100","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1136\/esmoopen-2019-000659_bb0105","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1136\/esmoopen-2019-000659_bb0110","unstructured":"MBorenstein, LHedges, JHiggins, et al. Comprehensive meta-analysis version 3. Available: https:\/\/www.meta-analysis.com\/index.php?cart=BHJU3327368"},{"key":"10.1136\/esmoopen-2019-000659_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"10.1136\/esmoopen-2019-000659_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v049.i05","article-title":"Closing the gap between methodologists and end-users: R as a computational back-end","volume":"49","author":"Wallace","year":"2012","journal-title":"J Stat Softw"},{"key":"10.1136\/esmoopen-2019-000659_bb0125","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","article-title":"Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen international consensus guidelines for the primary therapy of early breast cancer 2019","volume":"30","author":"Burstein","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000659_bb0130","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-Oncology services: rationale, organization, and implementation","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1136\/esmoopen-2019-000659_bb0135","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-019-05453-z","article-title":"A pooled analysis of the cardiac events in the trastuzumab adjuvant trials","volume":"179","author":"de Azambuja","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/esmoopen-2019-000659_bb0140","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1136\/esmoopen-2019-000659_bb0145","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1136\/esmoopen-2019-000659_bb0150","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1136\/esmoopen-2019-000659_bb0155","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","article-title":"Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin adjuvant trial (BIG 1-01)","volume":"32","author":"de Azambuja","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000659_bb0160","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv301","article-title":"The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study","volume":"108","author":"Goldhar","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/esmoopen-2019-000659_bb0165","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1002\/ijc.28234","article-title":"Cardiac toxicity in breast cancer patients treated with dual HER2 blockade","volume":"133","author":"Valachis","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1136\/esmoopen-2019-000659_bb0170","doi-asserted-by":"crossref","first-page":"iii65","DOI":"10.1093\/annonc\/mdz101","article-title":"Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial","volume":"30","author":"Eiger","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000659_bb0175","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000659_bb0180","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000659_bb0185","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1200\/JCO.2008.21.4577","article-title":"Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial","volume":"27","author":"Joensuu","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000659_bb0190","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the Herceptin adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2019-000659_bb0195","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/esmoopen-2019-000659_bb0200","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"Schneeweiss","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2019-000659_bb0205","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000659_bb0210","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000659_bb0215","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/annonc\/mdz130","article-title":"ER+\/HER2+ breast cancer: are we really de-escalating?","volume":"30","author":"de Azambuja","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000659_bb0220","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000659_bb0225","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy424.001","article-title":"LBA12_PRPERSEPHONE: 6 versus 12 months (M) of adjuvant trastuzumab in patients (PTS) with HER2 positive (+) early breast cancer (EBC): cost effectiveness analysis results","volume":"29","author":"Hulme","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000659_bb0230","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005195","article-title":"Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis","volume":"95","author":"Jawa","year":"2016","journal-title":"Medicine"},{"key":"10.1136\/esmoopen-2019-000659_bb0235","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS15-S5-04","volume":"76","author":"Slamon","year":"2016","journal-title":"Cancer Res"},{"key":"10.1136\/esmoopen-2019-000659_bb0240","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S1470-2045(13)70384-X","article-title":"Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study","volume":"14","author":"Jones","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920300223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920300223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2019-000659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:24:40Z","timestamp":1761855880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920300223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["S2059702920300223"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000659","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000659"}}